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a-Synucleina b s t r a c t
Parkinson’s disease (PD), Alzheimer’s disease (AD) and Amyotrophic lateral sclerosis (ALS) are neurode-
generative diseases hallmarked by the formation of toxic protein aggregates. However, targeting these
aggregates therapeutically have thus far shown no success. The treatment of AD has remained particu-
larly problematic since no new drugs have been approved in the last 15 years. Therefore, novel therapeu-
tic targets need to be identified and explored. Here, through the integration of genomic and proteomic
data, a set of proteins with strong links to a-synuclein-aggregating neurodegenerative diseases was iden-
tified. We propose 17 protein targets that are likely implicated in neurodegeneration and could serve as
potential targets. The human phosphatidylinositol 5-phosphatase synaptojanin-1, which has already
been independently confirmed to be implicated in Parkinson’s and Alzheimer’s disease, was among those
identified. Despite its involvement in PD and AD, structural aspects are currently missing at the molecular
level. We present the first atomistic model of the 5-phosphatase domain of synaptojanin-1 and its bind-
ing to its substrate phosphatidylinositol 4,5-bisphosphate (PIP2). We determine structural information on
the active site including membrane-embedded molecular dynamics simulations. Deficiency of charge
within the active site of the protein is observed, which suggests that a second divalent cation is required
to complete dephosphorylation of the substrate. The findings in this work shed light on the protein’s
binding to phosphatidylinositol 4,5-bisphosphate (PIP2) and give additional insight for future targeting
of the protein active site, which might be of interest in neurodegenerative diseases where
synaptojanin-1 is overexpressed.
 2020 The Authors. Published by Elsevier B.V. on behalf of Research Network of Computational and
Structural Biotechnology. This is an open access article under the CC BY license (http://creativecommons.
org/licenses/by/4.0/).1. Introduction
Age-related diseases are rapidly increasing in their frequency
due to longer life expectancy and can have devastating effects
upon the quality of life of sufferers [1,2]. At a cellular level, Parkin-
son’s disease (PD) and other neurodegenerative diseases, including
Alzheimer’s disease (AD) and Amyotrophic lateral sclerosis (ALS)
are linked to toxic protein aggregation [3,4]. However, targeting
these protein aggregates has not led to successful drug therapies.Small drug molecules are ineffective towards them and no new
therapies for Alzheimer’s disease have been approved in the last
15 years. It is, therefore, becoming increasingly important to iden-
tify novel targets for protein-aggregating neurodegenerative dis-
eases [5,6].
In PD, a-synuclein is of particular importance as it is the pri-
mary aggregating protein [7–9], its gene amplifications and muta-
tions may lead to PD [10–12]. Human neurons are complex cells
with long lifespans, therefore, a-synuclein toxicity has been
explored in the model eukaryotic organism, Saccharomyces cere-
visiae (budding yeast) [13–15]. Budding yeast cells do not have a
homologue to a-synuclein, therefore protein expression has been
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aggregation in yeast which leads to cell death [16].
The abundance of biological data from various experimental
sources (genomics, proteomics, metabolomics) offers unprece-
dented opportunities for data integration approaches for novel tar-
get identification [17]. Importantly, data integration is particularly
useful in analysing networks of protein interactions and is widely
used in developing understanding of how various cellular pro-
cesses are altered [18]. Importantly, it can inform novel targets
for atomistic studies, which is yet underutilized [19]. In this study,
we employed data integration upon two complementary studies of
a-synuclein toxicity: (i) genomics study by Khurana et al. and (ii)
proteomics study by Melnik et al. [15,20]. The first quantified the
effect of deletion and overexpression of various proteins on the
toxicity of a-synuclein in buddying yeast cells [14]. Khurana
et al. compared the lifespan of yeast cells that were modified to
express a-synuclein, with cells that expressed a-synuclein but
had one protein deleted or overexpressed. When the deletion or
overexpression of a protein significantly affected the lifetime of
the cells, this protein was labelled a disease modifier: cell death
enhancer or suppressor. The second dataset was collected from a
proteomic analysis of the perturbation in protein wide concentra-
tions of a-synuclein induced aggregation in buddying yeast, com-
pared to yeast that did not express the aggregating protein
[15,20]. By integrating data from both studies, we identified 17
potential human protein targets.
Among the proteins identified to be of interest, we chose the
protein polyphosphatidylinositol phosphatase INP53 for further
investigation and in particular, its human homologue,
synaptojanin-1 (synj1). Apart from being a cell death enhancer
when deleted in a-synuclein expressing cells and simultaneously
showing to be downregulated when a-synuclein was overex-
pressed, it has also already been independently identified that
the gene coding for the protein SYNJ1, is a particular PARK locus,
PARK 20 [21]. Additionally, synj1 is implicated not only in PD but
also in AD [22–25]. The primary substrates of synj1 are phospho-
inositides (PIPs) with phosphatidylinositol 4,5-bisphosphate PIP2
and phosphatidylinositol 3,4,5-bisphosphate PIP3 being among
the most important signalling lipids in membrane trafficking. An
imbalance in PIPs has previously been identified to be crucial in
many protein aggregating diseases, namely AD and PD [26,27].
The imbalance of phosphoinositides is heavily correlated to mal-
functions in synj1 activity, and mutations of synj1 itself are impli-
cated in various neurodegenerative diseases [22–26].
Synj1 has three domains. The main catalytic inositol 5-
phosphatase domain, the N-terminal Sac1 inositol phosphatase
domain, and a C-terminal proline-rich domain that plays a role
in protein–protein interactions related to vesicle endocytosis
[9,28]. Mutations in the Sac1 domain have already been linked
to the downregulation of PIPs and malfunctions in autophagy
[29].
Currently, experimentally resolved structures of the first two
domains of human synj1 are unavailable. We present here the
first atomistic model of the 5-phosphatase catalytic domain of
the protein both in membrane-free and membrane-embedded
molecular dynamics (MD) simulations. Additionally, we propose
that the protein active site involves two divalent cations. It is well
accepted that 5-phosphoinositide phosphatases are Mg-
dependent enzymes [30,31], with catalytic activity supported by
Mg2+ or Mn2+, however inhibited by Ca2+ and other divalent
cations [32]. This behaviour is often observed in phosphate cat-
alytic enzymes, demonstrating apoptotic regulatory role of Ca2+
[33]. We suggest that one of the Mg2+ ions has a role in activating
the water nucleophile, whereas the second Mg2+ stabilizes the
leaving group, similar to other enzymes using a two-metal ion
catalytic mechanism [34].2. Methods
2.1. Data integration
Two data sets were used for the data integration. The first data-
set was obtained by Khurana et al. [14] and was generated by com-
parison of the survival rate of yeast cells (S. cerevisiae) that were
modified to express a-synuclein to cells that expressed
a-synuclein but had one protein deleted or overexpressed. The
proteins were labelled as either toxicity ‘Suppressor’ (S) or
‘Enhancer’ (E), based on their toxicity modulating effect on the
a-synuclein expressing cells [14].
The second dataset was obtained by Melnik et al. [20]. The data-
set was generated using mass spectrometry-based label-free shot-
gun proteomics. a-Synuclein was expressed in yeast cells (S.
cerevisiae) by a galactose-induced promoter and the overall
changes of the protein abundancies in the proteome were com-
pared to control cells proliferating at the same time length but
transformed with an empty vector (EV). Protein abundance
changes were monitored at 6 h, 12 h, 18 h and 24 h after the
expression of a-synuclein. Proteins which had significantly per-
turbed abundance at 12 h and 18 h were selected in this work
(Table1 ESI and Fig. 3 ESI). Proteins perturbed at 6 h were not
included as very few proteins were observed to be altered at this
time suggesting that it is too early to observe the toxic effect on
the cell. The results at 24 h were also omitted as the cells were
dying and therefore many pathways were malfunctioning. The
median ratio for the protein concentration (a-synuclein expressing
cells vs. control) was the parameter used to classify the proteins as
up or down regulated. The value of 1.00 was chosen as a cut-off
point. If the average of the mean ratio value for the concentration
of the proteins between 12 h and 18 h was above 1.00, the protein
was classified ‘upregulated’, and if below 1.00, ‘downregulated’,
Fig. 3 ESI.
Following this, a combined protein dataset was generated. All of
the proteins that did not appear in the two initial datasets were
removed. The list of proteins that had significant results in both
studies were then further reduced by selecting only proteins with
human homologues, using the Yeast Mine Database [35]. Finally, it
was confirmed whether the protein had been previously linked to
aggregation diseases using Malacards database [36].2.2. Molecular dynamics simulations of Synaptojanin-1
The main catalytic 5-phosphatase domain of the human protein
synj1 does not currently have an experimentally resolved structure
in the protein data bank (PDB). Therefore, a homology modelling
server was used (SWISS-MODEL) [37] to create the three-
dimensional structure of the protein, using the amino acid
sequence from the Uniprot database [38] (code: O43426). The 3D
structure obtained from SWISS-MODEL was used for the MD sim-
ulations of synj1.
The 5-phosphatase domain of synj1 (residues 500–899) was
modelled using the template OCRL-1 in complex with a phosphate
ion (PDB code 4CMN) [30]. Residues 517–894 had a sequence iden-
tity of 36.47% to OCRL and a global model quality estimate of 0.64.
A ligand with an identical phosphate head group but shortened
tails was positioned manually along with the coordinating residues
and water molecules, for an initial comparison of the ligand to PIP2.
A single magnesium ion was added by visual inspection of known
crystal structures based on the alignment of the conserved cat-
alytic sites from within the 5-phosphatase family. Magnesium
ion was chosen as the catalytic ion in the active site, as human
5-phosphoinositide phosphatases are Mg2+-dependent [30], and
Zn2+, Ca2+ and other divalent ions (except for Mn2+) typically inhi-
Fig. 1. Effects of protein expression on a-synuclein cell toxicity. All proteins in the
diagram have human homologues. Protein downregulation (blue) or upregulation
(red) is also indicated in a-synuclein expressing cells. The circled area contains
proteins identified to be proteins of interest. The human homologues of the proteins
in italics with an asterisk are known to be involved in Parkinson’s or other
neurodegenerative diseases [46]. INP53 (bold) is the protein chosen for further
molecular dynamics modelling in this work. (For interpretation of the references to
colour in this figure legend, the reader is referred to the web version of this article.)
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PIP2 ligand and the magnesium ion was chosen to be the inositol
polyphosphate 5-phosphatase domain (IPP5C) of SPsynaptojanin
available in complex with inositol (1,4)-bisphosphate and a cal-
cium ion (PDB code 1I9Z) [39].
All Molecular Dynamics simulations were performed by using
the program NAMD [40]. The force field used in the simulations
was CHARMM36 with periodic boundary conditions and to evalu-
ate the non-bonded long-range interactions the particle mesh
Ewald method was utilised with a 12 Å cutoff [41,42]. The NPT
ensemble was maintained with a Langevin thermostat (310 K)
and an anisotropic Langevin piston barostat (1 atm). CHARMM-
GUI was used to set up the simulation box of side length
107.4 Å; neutralise and solvate the system; and determine the
charged state of all ionisable residues using a standard protocol
[43,44]. Ions randomly replaced water molecules using a Monte
Carlo method to neutralise the system using 3 K+ ions, then addi-
tional 111 K+ and 111Cl ions were added to create a salt concen-
tration of 0.15 M. Equilibration was completed using the standard
CHARMM-GUI protocol [43,44], with the addition of constraints
upon the distance between the Mg2+ ion and: (i) the phosphate
group on the fifth carbon of the inositol ring (5-P); (ii) Asp-359;
(iii) Glu-92; to be approximately 3 Å [40]. 8 ns of constrained
molecular dynamics simulations were completed using the con-
straints above, and 92 ns of non-constrained MD was run to test
the stability of the membrane-free structure.
The tails of the PIP2 were then reinserted to the structure of the
completedmembrane-free simulation, and the whole structure (in-
cluding the bound PIP2) was uploaded to the Orientation of Proteins
in the Membrane (OPM) server which gave a membrane alignment
for the system [45]. This alignment was then input into CHARMM-
GUI to add themembrane [43,44]. Themembranewas comprised of
90% phosphatidylcholine (PC), 5% phosphatidylserine (PS) and 5%
PIP2. To solvate the system the protein was inserted into cubic
pre-equilibrated TIP3P water box of with a dimensions 127.029 Å
 127.029 Å  129.809 Å. Ions randomly replaced water molecules
using a Monte Carlo method to neutralise the system, then an addi-
tional ions (231 K+ and 113Cl in total) were added to create a salt
concentration of 0.15 M. Six equilibration steps were conducted
based on standard CHARMM-GUI protocol [43,44]. 10 ns of con-
strained molecular dynamics was run, where constraints were
added upon the distance of 2 Å between the Mg2+ ion and the fol-
lowing: (i) 5-P; (ii) Asp-359; (iii) Glu-92; (iv) Asn-44; the phosphate
group on the fourth carbon of the inositol ring. These additional
constraint for the Asn-44 residue were added to establish if addi-
tional residues were required to stop the potassium ions approach-
ing the catalytic site. Two independent simulations of
unconstrained molecular dynamics each lasting 300 ns were com-
pleted from the constrained molecular dynamics in order to obtain
final structures for the Synaptojanin-PIP2 system.
3. Results and discussion
3.1. Data integration
We combined datasets from genome-wide and proteomic stud-
ies where: (i) the effects of protein deletion and overexpression on
cell death was studied, and where (ii) overall protein perturbation
levels were measured, in a-synuclein-expressing yeast cells. We
selected those proteins that were: (i) suppressors or enhancers of
cell death when deleted or overexpressed and (ii) had their con-
centration perturbed at 12 h and 18 h post a-synuclein expression.
This data integration highlighted 62 proteins of potential interest
in Parkinson’s, Alzheimer’s or other neurodegenerative diseases,
based on the proteins’ toxicity modulating effect and concentra-
tion, as quantified in a-synuclein-expressing yeast cells. We thenconsidered whether these proteins had human homologues,
whether they have already been implicated in any protein aggrega-
tion diseases, and the approximate function of the protein, if
known, in yeast. Upon removal of yeast specific proteins, which
are not of interest to human neurodegenerative disease, the pool
of proteins of interest was reduced to 47. The combined integrated
data is visually represented in Fig. 1.
We further narrowed down the list of proteins to have most sig-
nificance by proposing that the candidates of most interest for us
would be those that either: enhance toxicity when deleted and
are significantly downregulated in a-synuclein induced cells; sup-
press toxicity when overexpressed and their concentration is
downregulated in a-synuclein induced cells; enhance toxicity
when overexpressed and are significantly upregulated. These pro-
teins are represented in Fig. 1 within the circled area.
This method of data integration highlights 17 proteins (Table1
ESI). Four of the 17 proteins (INP53, RAD27, YPK9 and POR1) have
already been independently confirmed to be implicated in Parkin-
son’s, Alzheimer’s or other neurodegenerative diseases caused by
protein aggregation [36]. Therefore, our analysis demonstrates that
data integration is indeed useful in locating existing and novel pro-
tein targets that directly impact the toxicity of a-synuclein in
humans, as well as in yeast, and therefore might play an important
role in neurodegenerative diseases such as PD or AD.
Note that some of the proteins appear in multiple sections:
YPK9, RTS1, RPS14A. For all three, cell toxicity is enhanced when
the proteins are deleted, and suppressed when they are overex-
pressed. This is consistent with their roles as being overall needed
by the cells to survive in the a-synuclein-rich environment. Inter-
estingly, however, while RTS1, RPS14A are accordingly upregulated
by the cells, YPK9 appears downregulated. YPK9 therefore has a
key function, which appears to be impaired by a-synuclein overex-
pression, as the cells are unable to produce enough YPK9 to help
cell survival.
YPK9’s human homologue, ATP13A2, is also identified by vari-
ous independent measures as a key protein in PD. It is one of the
PARK genes identified in human disease, PARK9, its mutations
are associated with Spastic Paraplegia (SPG78), Kufor-Rakeb syn-
drome and neuronal ceroid lipofuscinosis [47].
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protein S14. It is a member of the ribosome, a central protein of
the ribosomal protein subunit S40. It has many diverse roles and
it is required for ribosome assembly and 20S pre-rRNA processing,
therefore this might lead to its consistent role needed for cell sur-
vival [48–51].
RTS1 is a homologue of the mammalian B0 subunit of PP2A and
encodes a serine/threonine-protein phosphatase [52]. It is a central
protein with several diverse roles: it is required for maintenance of
septin ring organization during cytokinesis, for ring disassembly in
G1 and for dephosphorylation of septin [53]. Similarly to RPS14A, a
diverse regulatory function might be the reason for it being consis-
tently beneficial for cell survival.3.2. Synaptojanin-1 as potential drug target
Next, we selected synj1 to investigate further using atomistic
molecular simulations. In our data integration, synj1 showed
strong correlation with a-synuclein toxicity in the following ways:
(i) when deleted the protein increased the rate of cell death; (ii)
when a-synuclein was expressed in buddying yeast cells, the con-
centration of synj1 was downregulated compared to empty vector
(EV) control cells that did not express a-synuclein. Based on these
results the protein shows to be directly or indirectly involved in
the toxicity of the aggregating protein a-synuclein. Furthermore,
it is also independently confirmed by genetic analysis of PD
patients’ genome that mutations of the synj1 gene have strong cor-
relation to Parkinson’s disease [23]. Synj1 is also a PARK gene
(PARK20) [21]. In addition, mutations of synj1 are also correlated
with Alzheimer’s disease suggesting that it is a crucial protein in
neurodegenerative diseases [25].
Synj1 does not currently have a crystallographically resolved
structure except for its proline-rich domain, therefore structural
studies will offer valuable insights for future drug discovery pro-
jects. We were also able to identify suitably accurate homology
model template for the main catalytic 5-phosphatase domain, with
an active site that is almost identical within the same phosphataseFig. 2. Predicted close functional partners of synj1. All proteins shown in larger nodes
unknown 3D structure. Grey lines: protein–protein interaction; green: protein-chemical.
expression. Generated in high confidence (0.700) [54]. (For interpretation of the referen
article.)phosphoinosidtide subfamily. Other proteins of interest without
available structure had lower sequence identity to template struc-
tures in the Protein Data Bank, therefore, they were less suitable
candidates for molecular dynamics simulations at the time of the
project start.
We first determined the protein–protein interaction network of
synj1 using the STRING database [54] (Fig. 2, full list of proteins
and their corresponding function in Table 2 ESI). This network sug-
gests that synj10s primary functional partners are proteins involved
indirectly or directly in synaptic vesicle endocytosis/vesicle traf-
ficking, either through their role in PIPs regulation (signalling
kinases) or in the cascade towards synaptic vesicle endocytosis.
Synj1 is therefore likely mainly implicated in neurodegenerative
diseases via its role in phosphatidylinositol signalling dynamics,
and does not have direct effect on protein aggregation [27,29,55].
As part of the synaptic vesicle trafficking pathway, one of its pri-
mary catalytic functions is the dephosphorylation of the 50P of
the PIP moiety in Phosphatidylinositol 4,5-bisphosphate (PIP2)
and Phosphatidylinositol 3,4,5-bisphosphate (PIP3). In this work,
we have focused on the 5-phosphatase domain of the protein,
which mainly dephosphorylates PIP2, a crucial phosphoinositide
for healthy nerve function, with known effects on neurodegenera-
tion [56,57].3.3. Homology modelling of Synaptojanin-1
We created a homology model of synaptojanin-1 based on the
human inositol polyphosphate 5-phosphataseOCRL-1 (4CMN)
[58], which has very high active site sequence identity to
synaptojanin-1. There are six residues within 5 Å of the Mg2+ of
our model that are all conserved between the model and the tem-
plate protein (Fig. 1 ESI). This evidence demonstrates that the
active site of synj1 can be reliably modelled based on OCRL. Addi-
tionally, charged residues are also highly conserved, which is an
expected outcome for proteins with identical functionality, and
additionally supports the likelihood of a reliable homology model.
The sequence of synj1 (5-phosphatase domain) was also alignedwith cartoon have determined 3D structure, the small nodes represent proteins of
Active interaction sources: experiments, gene fusion, databases, co-occurrence, co-
ces to colour in this figure legend, the reader is referred to the web version of this
Fig. 3. The overall conserved fold (a) and the evolutionary conserved residues (b) of 5-phosphoinositide phosphatase proteins with their code from the Protein Data Bank
(PDB): yeast fission synaptojanin (1I9Z, cyan) [39], human OCRL-1 (4CMN, green) [58], human SHIP2 (4A9C, magenta) [62], human I5P2 (3MTC, orange) [58] and human Synj1
model (purple) [40,58,62]. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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(Sequence in Fig. 2 ESI) [59–61]. Comparison of 5-phosphatases
within the same subfamily with defined crystal structures: yeast
fission synaptojanin (1I9Z) [39], human inositol polyphosphate 5-
phosphatase OCRL-1 (4CMN) [58], human phosphatidylinositol
3,4,5-trisphosphate 5-phosphatase 2 SHIP2 (4A9C) [62] and human
Type II inositol 1,4,5-trisphosphate 5-phosphatase I5P2 (3MTC)
[58] shows the conserved overall three-dimensional fold (Fig. 3a)
and evolutionary conserved residues in close proximity to the
active site (Fig. 3b).
The completed homology model of the 5-phosphatase domain
was compared to fission yeast synaptojanin (PDB:1I9Z) [39] with
an overall very similar fold (Fig. 4a). It was observed that the
Asp, His and Glu, the primary conserved active site residues, are
located in the binding pocket for both the fission yeast synapto-
janin crystal structure and the homology model of human synj1
(Fig. 4b). The conserved residues correspond to Asp-359, His-360
and Glu-92 in the homology model.Fig. 4. Comparison of the homology model of the 5-phosphatase domain of human syna
(PDB: 1I9Z) [39]. Overall fold of the 5-phosphatase domain in both proteins (a), conserved
figure legend, the reader is referred to the web version of this article.)4. Molecular dynamics simulations
4.1. Membrane-free molecular dynamics simulation
The flexibility of the whole protein was determined by RMSD
calculations, confirming that the most flexible parts lie outside of
the catalytic domain, (RMSD in Fig. 4 and Fig. 5 ESI). Fig. 5 shows
the protein coloured according to the RMSD value with red signify-
ing flexible regions and blue the more rigid parts. The flexible
regions most likely belong to areas that are involved in protein–
protein interactions within the synj1 or with external binding part-
ners, as the simulations only use one domain of the protein and the
interacting partners are missing from the simulations. This can be
seen by the more flexible behaviour occurring at the surface of the
system, mainly involving loops. This does not affect the active site
or the PIP2 interaction as the highly flexible regions are not within
significant proximity of the active site. The conformation of the
synj1 active site was first probed in a membrane-free simulationptojanin-1 (green) with the crystal structure of fission yeast synaptojanin (yellow),
residues within active site (b). (For interpretation of the references to colour in this
Fig. 5. Protein coloured according to RMSD calculations of the full system (a) and catalytic domain only (b).
K. Jenkins et al. / Computational and Structural Biotechnology Journal 18 (2020) 1032–1042 1037and remained stable throughout the MD simulations, with an
RMSD of 5 ± 1 Å. It was observed that potassium ions often
appeared very close to the active site and remained there for
extended periods of time. This was a surprising result, as currently
the crystal structures of 5-phosphatases within the 5-
phosphoinositide phosphatase family have not observed two metal
ions at the active site [31,39,58].4.2. Membrane-embedded simulations
The unexpected presence of the potassium ions within the
active site was further investigated in membrane-embedded simu-
lations. The phospholipid bilayer consisted of 90% phosphatidyl-
choline (PC), 5% phosphatidylserine (PS) and 5% PIP2. The
simulation setup of the system is shown in Fig. 6, it included the
lipid bilayer, PIP2 ligand, protein, and the single Mg2+ cation. The
PIP2 tail was indeed embedded in the membrane, and the protein
located on top of the lipid bilayer allowed the phosphosugar head-
group of the PIP2 to bind to the synj1 active site.Fig. 6. Simulation setup for the membrane-embedded simulations (a). The centres of
spheres and grey sticks), bound PIP2 ligand (blue sticks), and protein (yellow cartoon)
structure of PIP2 (c). (For interpretation of the references to colour in this figure legendTwo independent simulations were conducted over 300 ns
each. The stability of the system was assessed via the radius of
gyration and solvent accessible surface area of the protein
(Fig. 7). The independent simulations present variation in values
within a narrow range, suggesting the simulations are stable. Fur-
ther analysis of the system found that the distances between both
the bilayer centre of mass and the protein centre of mass, and the
PIP2 and the magnesium ion respectively, remained stable
throughout the simulation (Fig. 7). Therefore, the protein did not
penetrate the bilayer, neither did the PIP2 ligand penetrate further
into the protein.
It was observed during both simulations that potassium ions
appeared for prolonged periods of time within the active site, as
quantified in Fig. 8. The active site is defined as distance of 4.5 Å
or less to the 50P atom of the PIP2 ligand. Consequently, if a potas-
sium ion appears within 4.5 Å of the 50P, it is considered to reside
within the active site. There were three cases in the course of the
simulation – either 0, 1 or 2 potassium ions appeared within the
active site. We found that during the first and second simulations,mass (black spheres) for each component of the simulation: lipid bilayer (orange
are shown. In membrane-free simulations the ligand was modified (b) from the
, the reader is referred to the web version of this article.)
Fig. 7. Stability measures of the synaptojanin-1 complex. (a) Radius of gyration and (b) solvent accessible surface area (SASA) distributions of the protein with a resolution of
0.03 Å and 20.0 Å, respectively. The area under each probability distribution curve is normalized to unity. (c and d) Distances between centre of mass positions projected onto
the z axis for simulations 1 and 2, respectively (pink – lipid bilayer and protein; olive – lipid bilayer and PIP2; blue – Mg2+ and PIP2). (For interpretation of the references to
colour in this figure legend, the reader is referred to the web version of this article.)
Fig. 8. K+ ions within 4.5 Å of the active site during the course of simulation one (a) and simulation two (b). Percentage of 0, 1, and 2 K+ ions, respectively, during simulation
one (c) and simulation two (d).
1038 K. Jenkins et al. / Computational and Structural Biotechnology Journal 18 (2020) 1032–1042over 70% and 25% of the time respectively, there was at least one
potassium ion within 4.5 Å of 50P. This suggests that a second pos-
itive ion is required to balance the negative charge within the bind-
ing pocket. As can be seen in Fig. 8a and b, the potassium ions
approach the active site and then go away, with the number ofpotassium ions fluctuating constantly between 0, 1 or 2. It was
observed that the localisation of the potassium cations within
the active site was dependent on the orientation of the 40phos-
phate group of the PIP2 ligand. During the second simulation the
40phosphate group undergoes rotation, which alters the site where
Fig. 9. Main K+ binding sites A and B during simulation 1 (a) and simulation 1 and 2 (b). K+ population from simulation one is coloured in wheat, K+ population from
simulation two is coloured in orange. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) The positions
of the K+ ions are shown relative to the active site Mg2+-binding residues and the Mg2+ cation of the first simulation frame.
K. Jenkins et al. / Computational and Structural Biotechnology Journal 18 (2020) 1032–1042 1039the K+ cations localise within the active site. Fig. 9 illustrates the
two preferential binding sites for the potassium ions, defined here
as binding site A and B. If the 40phosphate group of the PIP2
remains in its original orientation for the entire 300 ns of the sim-
ulation, then the cations preferentially cluster within the same
spatial region in the active site and form only one binding site
(Fig. 9a). In a rotated orientation where the phosphate groups of
the PIP2 40 and 50 point in opposite directions, the K+ cations cluster
in two locations, as depicted in Fig. 9b.4.3. PIP2 dephosphorylation requires 2-metal-ion active site
Our MD simulations showed that the catalytic site of synj1 has a
positive charge deficiency, attracting potassium ions to approach
and remain within 4.5 Å of the catalytic site. Given the consistent
location of these potassium ions, this suggests that synj1 functions
as a two-metal ion catalytic system. Currently, all known crystal
structures of phosphoinositide 5-phosphatases have been resolved
with only a single Mg2+ ion bound in the active site [30,39,58].
However, our simulations used the catalytically active ligand,
PIP2, as opposed to the inactive protein–ligand complexes with
synthetic derivatives resolved structurally. Furthermore, we also
included the membrane environment not present in these crystal-
lographic structures. We found that PIP2 does not significantly
change its conformation with respect to the protein or the lipids
but rather the potassium ions do approach the highly conserved
catalytic residues, further supporting the suggestion that one mag-
nesium ion may be insufficient. The occupancy of the potassium
binding pocket within the active site continuously changes
between 0, 1 and 2 ions during the course of the simulations, high-
lighting the openness of the binding site, which is likely only stable
once the catalytic complex is correctly assembled. This could pro-
vide an explanation for the lack of crystallographic observation of
the second metal ion.
Independently from our current work, various studies suggest
that 5-phosphatases operate via the same catalytic mechanism as
Mg2+-dependent DNA restriction endonucleases, including the
members DNase I and the apurinic/apyrimidinic base excision
repair endonuclease Ape1 [63,64]. The conserved catalytic mech-
anism of the same 5-phosphate-type cleavage reaction is sup-
ported by evolutionarily strongly conserved amino acidsequence motifs within the active site (Fig. 6, ESI) [64]. Various
endonuclease structures have been resolved with 2 cations within
the active site, further suggesting that synj1 might also operate as
a two-ion catalytic system [34,65]. Previous MD simulations of
Ape1 also suggested the possible transient transfer between the
two metal ion locations, termed ‘‘moving metal mechanism”
[66], however, we do not observe evidence for such a mechanism
in our simulations.
Additionally, biochemical experiments using various Mg2+ and
Ca2+ concentrations also support the two-metal ion catalytic mech-
anism. Two metal-binding sites, each with a distinct binding affin-
ity, are expected to yield biphasic inhibition curves when titrated
with a non-productive metal. These bimodal effects were observed
for APE1 further supporting that two metal ions are required for
the catalytic reaction [34].4.4. Synaptojanin-1 binding to PIP2 and the potential for drug therapy
The importance of understanding the binding mechanism
between synaptojanin-1 and the phosphatidylinositol phosphates
has been already established. This understanding creates the
potential for a new drug target. The MD simulations discussed in
this work have achieved new insight into this binding process. It
was shown that the PIP2 bound to the synaptojanin-1 complex is
stable and relatively open as the protein needs to also interact with
the membrane surface to bind to PIP2. This opens the possibility of
drug molecules potentially interfering with the binding process,
which could be used to decrease the activity of the protein in neu-
rodegenerative diseases where upregulation increases the
pathogenicity of the disease, for example in Alzheimer’s disease.
The decreased expression of synaptojanin-1 in AD has been shown
to be protective and aids in amyloid-beta clearance [9,22]. Any
drug created would need to be carefully administered as uncon-
trolled downregulation of the protein can also be harmful, as seen
in our data integration results. The drug target would also need to
interact preferentially with synj1 over the other phosphatidylinos-
itol 5-phosphatases, all of which have very similar catalytic sites.
Due to this, it may be worthwhile investigating whether targeting
other regions of synj1 may be preferential. Alternatively, a drug
target may bind to a synj1-specific surface that interferes with
the membrane interactions, preventing PIP2 binding.
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The utilisation of yeast to predict the most important proteins
in neurodegenerative diseases in humans has been found to have
many benefits. As yeast is a much simpler cell than a neuron and
is a single-celled organism, it significantly reduces the complexity
of the problem. It also has a much shorter lifespan making it easier
to study and collect sufficient data upon [67]. In humans, we gen-
erally use post-mortem samples or positron emission tomography
(PET), which are potentially not very effective methods for identi-
fying early markers and causative processes of a disease, as they
are not single cell methods [68]. Ideally, preferred therapies inter-
vene before significant cell death, cognitive decline and bradykine-
sia occur, enabling a higher quality of life for patients. Many
proteins that have been discovered to have an effect on human dis-
ease progression are identified by mutations that cause harmful
effects in the protein, and subsequently increase the likelihood or
speed of disease progression [69]. Using mutations to identify pro-
teins related to disease while useful, does not necessarily aid in
understanding the sporadic disease, or general disease pathway.
It is possible to identify proteins that suppress disease progression
in wild type cells, but when mutated are unable to perform their
function and lead to increased disease progression, as well as those
that are already actively exacerbating the disease in wild type cells.
Using yeast where high throughput genomic and proteomic stud-
ies are regularly conducted, it is possible to combine multiple data-
sets in the hope to provide more insight into the effect of the non-
mutated proteins on neurodegenerative diseases’ progression
[13,14,16]. However, arguably, the most significant drawback of
this method is that neurodegenerative diseases are often develop-
ing at the synapse, which is not present in yeast. For this reason,
any yeast-based method, including the data integration found in
this work, cannot identify any neuron-specific proteins or path-
ways but rather generic cell pathways that are conserved in both
humans and yeast, and so invariably they will be proteins that
are highly conserved across all eukaryotes. This is the underlying
reason why the 17 candidate proteins found are primarily involved
in processes or organelles that are ubiquitous across eukaryotes;
with many linked to the mitochondria and its associated processes.
Data integration is still a very powerful tool as it has been possible
not only to investigate the effect of a-synuclein aggregation upon
protein concentrations in the cell, but also how these perturbations
in protein concentration may be altering the toxicity of aggregation
[14,20].5. Conclusions
The wealth of biological information currently being produced
requires new approaches to interpret and utilise the data so that
we maximally filter useful information. Data integration is one
possibility that could enable us to reuse data that is currently
under-utilised. This is particularly beneficial as it does not require
conducting more experiments to gain more information. Using this
principle of data integration, two large scale studies of a-synuclein
induction in budding yeast were analysed and used to identify 17
proteins that could be of interest in human PD and AD. Most of
these 17 proteins were found to be related to human diseases,
either directly or indirectly.
Among those, we chose to investigate further the 5-
phosphatase domain of the regulatory lipid phosphatase
synaptojanin-1. By dysregulation of various PIPs, the malfunction
of synj1 is linked to the decrease of cell health and increase of pro-
teomic stress. Synaptojanin-1 dephosphorylates the phosphatidyli-
nositol PIP2 at the synapse membrane. The catalytic function is
carried out through an interaction with an essential coordinatingmagnesium cofactor. Through all-atom MD simulations including
the membrane and the PIP2-bound protein, we observed that the
proposed catalytic site was stable, but potassium ions persistently
approached the binding pocket. This suggests that another positive
charge is required for a catalytically active complex. Therefore, we
propose that synj1 is likely using a two-metal ion catalytic mech-
anism for its phosphatase function. Current human phosphoinosi-
tide 5-phosphatases are all resolved crystallographically with only
a single metal ion at the active site. Future work on synj1 could
confirm our results via high-resolution crystal structures, or by
biochemical measurements on the effects of mutations at the cat-
alytic site or using Mg2+ concentration-dependent catalytic rate
measurements. This would be particularly beneficial in future tar-
geting of the active site.
Our work identifies potential novel targets for a-synuclein
aggregating diseases. Furthermore, it provides the first atomistic
investigation of the human synj1 main 5-phosphatase catalytic
domain. Our novel structural information could potentially enable
the design of a small molecule inhibitor that could prevent or
destabilise PIP2 binding, leading to a novel avenue for disease ther-
apy where decreasing synj1 activity can be beneficial.CRediT authorship contribution statement
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